Please login or create an account. If you do not have access to this content, you will be shown a 30 second preview and licensing options.
- Presentation
Dermatomyositis Evaluation, Malignancy and Lung Screening, and Emerging Treatments
Description
The talk reviewed evaluation and management of dermatomyositis using a practical “three M’s and an L” framework: myositis-specific antibodies, muscles, malignancy, and lungs. It emphasized ordering myositis antibody panels through available lab pathways and assessing muscle involvement with history, exam, CK, LDH, and aldolase, using MRI when findings are unclear because it is highly sensitive and can often replace muscle biopsy in indeterminate cases. For malignancy screening, it described recent IMACS risk-stratified guidelines that categorize patients into high-, moderate-, or low-risk groups based on factors such as classic dermatomyositis, TIF1-gamma, NXP2, age over 40, dysphagia, necrosis, persistent activity, clinically amyopathic disease, MDA5, SAE1, ME2, and male sex, with corresponding basic and enhanced screening recommendations. For lung disease, it highlighted baseline pulmonary function testing for all patients, with early high-resolution CT chest for those with high-risk features such as anti-synthetase syndrome, MDA5, mechanic’s hands, arthritis/arthralgias, and ulcerating lesions. The treatment section reviewed standard options including sun protection, topical therapies, corticosteroids, methotrexate, mycophenolate, and IVIG, noting that hydroxychloroquine has limited benefit and frequent rash. It then discussed newer and emerging therapies, especially JAK inhibitors, anifrolumab, and investigational agents targeting interferon pathways, underscoring that the therapeutic landscape for refractory dermatomyositis is rapidly expanding and becoming more effective.
View moreConclusions
- Dermatomyositis workup should systematically assess myositis-specific antibodies, muscle involvement, malignancy risk, and interstitial lung disease.
- Myositis-specific antibodies are not required to diagnose dermatomyositis, but they help predict systemic complications and guide surveillance.
- Muscle disease can be present even with normal CK, so exam, aldolase/LDH, and MRI are important for indeterminate cases.
- MRI is increasingly favored over muscle biopsy for confirming muscle involvement because it is noninvasive and highly sensitive.
- Cancer screening should be risk-stratified using clinical and serologic high-risk features rather than a one-size-fits-all approach.
- High-risk patients need broader baseline malignancy screening and repeated surveillance, while lower-risk patients need less intensive evaluation.
- Patients with dermatomyositis should be screened for lung disease at baseline, and high-risk patients should get both PFTs and high-resolution chest CT early.
- Clinically amyopathic patients and those with subtle symptoms still require ongoing follow-up because muscle or lung disease may emerge later.
- Cutaneous disease has a major quality-of-life burden in dermatomyositis and often warrants active treatment even when muscle disease is limited.
- Hydroxychloroquine monotherapy is usually inadequate for dermatomyositis and is limited by low response rates and frequent drug eruptions.
- Traditional agents such as methotrexate and mycophenolate remain useful first-line therapies, but they often work slowly and are not dermatomyositis-specific.
- IVIG is an effective, now-approved option for severe or refractory skin and muscle disease and may be used earlier in very active cases.
- JAK inhibitors show meaningful benefit in refractory dermatomyositis and are becoming an important therapeutic option.
- Targeted therapies against interferon pathways, including brepocitinib, dazukibart, anifrolumab, and efgartigimod, suggest the treatment landscape is rapidly expanding.
- Overall, dermatomyositis is becoming more treatable, with growing opportunities for disease control and even clearance in refractory patients.
- PMID: 31279808
- PMID: 31279813
- PMID: 32096127
- PMID: 30997152
- PMID: 34118766
- PMID: 37945774
- PMID: 38973714
- ARCH DERMATOL/VOL 146 (NO. 7), JULY 2010
- Femia AN, Vleugels RA. Data, 2015.
- Study of Tofacitinib in Refractory Dermatomyositis: An open-label pilot study of ten patients. Arthritis Rheumatol. 2021.#10.1002/art.41602
- Neurology 2002;59:1170-82
- Ann Neurol 2005;57:664-78
- Ann Neurol 2010;67:53-63
- Arth Rheum 2007;56:3784-92
- Genes Immun 2011; doi 10.1038
- Ann Rheum Dis 2011;70:831-6
- PloSOne 2012;7:e29161
- Efficacy, safety, and target engagement of dazukibart, an IFNβ specific monoclonal antibody, in adults with dermatomyositis: a multicentre, double-blind, randomised, placebo-controlled, phase 2 trial.#10.1016/s0140-6736(24)02071-3
- PEDIATRICS Volume 155, Issue 4, April 2025:e2024067481.
- Rapid Improvement in Recalcitrant Cutaneous Juvenile Dermatomyositis With Anifrolumab Treatment#10.1001/jamadermatol.2023.4744
- Chinoy et al EULAR 2025 Phase 2 ALKIVIA Topline Results Oral Presentation